Related Experiment Video
Updated: Jun 4, 2026

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
Published on: May 9, 2018
Alfuzosin induced thrombocytopenia after treatment for benign prostatic hyperplasia
Sebnem Güner1, Bircan Mutlu, Ekrem Güner
1Istanbul Training and Research Hospital, Department of Hematology, Istanbul, Turkey.
Abstract:
We report on 1 case of alfuzosin induced thrombocytopenia after treatment for benign prostatic hyperplasia. This side effect has been recognized 3 months after the alfuzosin treatment. The diagnosis was made by complete blood count (CBC). Peripheral blood smear of the patient was referred to an hematologist to exclude pseudothrombocytopenia and review of the peripheral smear confirmed the decreased platelets with no clumping. Manual count of platelets was similar to the result of complete blood count. After cessation of alfuzosin treatment thrombocytopenia improved and thrombocyte count reached to normal on week 2 following the discontinuation of treatment. Recovery of thrombocytopenia after discontinuation of alfuzosin treatment and recurrent depletion of platelet count after initiation of alfuzosin, supports our thoughts about drug-induced thrombocytopenia (DITP) caused by alfuzosin. The patient was prescribed different alfa blocker and he faced no problem.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Urodynamic Studies: Uroflowmetry
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Urinary Tract Calculi III: Medical Management

